Mornings Earnings Wrap Up for Tuesday, March 14, 2023
Top Earnings News
Caleres Beat Consensus Estimates
Caleres (CAL) reported earnings of $0.65 per share on revenue of $696.43 million for the fiscal fourth quarter ended January 2023. The consensus earnings estimate was $0.64 per share on revenue of $670.72 million. The company beat consensus estimates by 1.56% while revenue grew 2.53% on a year-over-year basis.
The company said it expects first quarter earnings of $0.92 to $0.97 per share on revenue of $691.01 million to $705.71 million and fiscal year earnings of $4.10 to $4.30 per share on revenue of $2.97 billion to $3.0275 billion. The current consensus estimate is earnings of $1.02 per share on revenue of $770.12 million for the quarter ending April 30, 2023 and earnings of $4.17 per share on revenue of $3.03 billion for the year ending January 31, 2024.
Caleres is the home of today’s most coveted footwear brands and represents a diverse portfolio spanning all of life’s styles and experiences.
J.Jill Beat Consensus Estimates
J.Jill (JILL) reported earnings of $0.11 per share on revenue of $147.65 million for the fiscal fourth quarter ended January 2023. The consensus estimate was a loss of $0.10 per share on revenue of $143.00 million. The company beat consensus estimates by 210.00% while revenue grew 1.72% on a year-over-year basis.
The company said it expects first quarter revenue of approximately $149.2 million. The current consensus revenue estimate is $158.6 million for the quarter ending April 30, 2023.
J.Jill is a premier omnichannel retailer and nationally recognized women’s apparel brand committed to delighting customers with great wear-now product. The brand represents an easy, thoughtful and inspired style that reflects the confidence of remarkable women who live life with joy, passion and purpose. J.Jill offers a guiding customer experience through more than 265 stores nationwide and a robust e-commerce platform.
Top Earnings Surprise
LARIMAR THERAPT Beat Consensus Estimates
LARIMAR THERAPT (LRMR) reported a loss of $0.21 per share on revenue of $0.00 million for the fourth quarter ended December 2022. The consensus estimate was a loss of $0.78 per share. The company beat consensus estimates by 73.08%.
Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
Top Negative Surprise
McEwen Mining Missed Consensus Estimates
McEwen Mining (MUX) reported a loss of $0.79 per share on revenue of $28.24 million for the fourth quarter ended December 2022. The consensus estimate was a loss of $0.23 per share. The company missed consensus estimates by 243.48% while revenue fell 19.31% compared to the same quarter a year ago.
McEwen Mining Inc is a mining and minerals exploration company focused on precious and base metals in Argentina, Mexico and the United States.
Top Revenue Growth
Emerald Expositions Events Reported Earnings
Emerald Expositions Events (EEX) reported earnings of $0.06 per share on revenue of $93.60 million for the . . Revenue grew 127.74% on a year-over-year basis.
Emerald is a leader in building dynamic, market-driven business-to-business platforms that integrate live events with a broad array of industry insights, digital tools, and data-focused solutions to create uniquely rich experiences.
Top Negative Guidance
MoneyLion Sees Revenue Below Estimates
MoneyLion Inc (ML) said it expects first quarter revenue of $85.0 million to $88.0 million. The current consensus revenue estimate is $96.30 million for the quarter ending March 31, 2023.
MoneyLion is a mobile banking and financial membership platform that empowers people to take control of their finances.